Omniscient Neurotechnology Pty Limited

Based in Australia, Omniscient Neurotechnology specializes in advanced neurotechnology solutions, focusing on connectomics to enhance understanding of brain connectivity for improved neurological care. Omniscient Neurotechnology, founded in 2019 in Haymarket, Australia, provides innovative neurotechnology solutions. The company recently raised USD 27. 2 million in series D funding co-led by OIF Ventures and the Australian National Reconstruction Fund Corporation, with participation from individual investors and other unspecified investors.

The investment will support the commercialization of their Quicktome platform and expansion of their data science team. Stephen Scheeler serves as CEO, while the company was co-founded by Michael Sughrue, Stephane Doyen, and Stephen Scheeler. The company has completed 6 deals to date, with the most recent deal occurring on 01/06/2026. Omniscient Neurotechnology specializes in advanced neurotechnology solutions, focusing on connectomics—the study of brain connectivity.

Their core product, Quicktome, is an AI-powered connectomic analysis platform that processes vast amounts of neural data to produce individualized insights into a patient's unique brain networks and functions. This platform aids clinicians in creating personalized treatment roadmaps for various neurological conditions such as depression, Alzheimer's disease, and stroke. Omniscient serves a diverse clientele that includes neurosurgeons, psychologists, and researchers, primarily in North America, Europe, and parts of Asia. The company's solutions are designed to enhance surgical planning and patient outcomes by providing actionable intelligence prior to critical surgeries.

Omniscient Neurotechnology generates revenue through a business-to-business model, primarily engaging with healthcare institutions and professionals who utilize their flagship product, Quicktome. Transactions typically occur via subscription agreements or contractual partnerships where clients pay for access to the platform and its associated services. This structure enables institutions to integrate Quicktome into their diagnostic and treatment workflows, facilitating ongoing revenue streams for the company. The pricing model reflects the comprehensive analytics and insights provided by the platform, allowing healthcare providers to enhance patient care effectively while driving the company's financial performance.

The revenue generated supports continued research and development efforts in the field of brain health and analytics. In June 2026, Omniscient Neurotechnology Pty Limited raised USD 27. 2 million in series D funding co-led by OIF Ventures and the Australian National Reconstruction Fund Corporation, with participation from individual investors and other unspecified investors. The company will use the funding to expand its platform and develop clinical applications for BCI, stroke, and movement disorders.